Gore L, et al. - In this phase II, open-label, nonrandomized prospective trial, which is the largest prospective trial to date in children with chronic myeloid leukemia in chronic phase (CML-CP), it was demonstrated that dasatinib is a safe, effective treatment of pediatric CML-CP. Findings showed that target responses to first- or second-line dasatinib were met early. Researchers observed deep molecular responses. In pediatric patients vs adult patients, the similar safety of dasatinib was noted, however, there were no cases of pleural or pericardial effusion or pulmonary arterial hypertension.